Recent progress in deciphering the molecular basis of carcinogenesis is of utmost importance to the development of new anticancer strategies. To this end, it is essential to understand the regulation of both normal cell proliferation and its alterations in cancer cells. We have previously demonstrated that in ras-transformed cells there is an increased level of phosphorylcholine (PCho) resulting from a constitutive activation on choiline kinase (ChoK). The importance of ChoK for the regulation of cell proliferation has also been proposed since an inhibitor for this enzyme, hemicholinium-3 (HC-3), drastically reduces entry into the S phase after stimulation with growth factors. Here we report the synthesis of several new compounds which are highly speci®c inhibitors for ChoK, with up to 1000-fold or 600-fold increased inhibitory activity, compared to HC-3 under ex vivo or in vitro conditions respectively. These novel compounds also drastically reduce entry into the S phase after stimulation with speci®c growth factors. A more profound inhibition of cell proliferation was observed in ras-, src-and mos-transformed cells in the presence of ChoK inhibitors, compared to their parental, untransformed NIH3T3 cells. By contrast, this eect was not observed in fos-transformed cells. While ras, src and mos transformation is associated with elevated levels of ChoK activity, fos-induced transformation does not aect ChoK activity. The inhibitory eect on proliferation of the new compounds correlates with their ability to inhibit the production of phosphorylcholine in whole cells, a proposed novel second messenger for cell proliferation. These results strongly support a critical role of choline kinase in the regulation of cell growth and makes this enzyme a novel target for the design of new antiproliferative and anticancer drugs.
Introduction
Anticancer therapy is based mostly upon the use of drugs with antiproliferative activity to such an extent that the most frequently used ones belong to the group of cytotoxic drugs (De Vita et al., 1993; MacDonald et al., 1995) . Their mechanism of action is based upon the fact that they are most eective towards cancer cells because of their high rate of proliferation, in comparison to normal cells which have lower proliferative rates (MacDonald et al., 1995) . Fastgrowing normal cells, such as hematopoyetic precursors and epithelial cells of the intestine and other tissues, are also negatively aected by therapeutic treatments. As a consequence, stem-cells toxicity which produces anemia and immunosuppression and dysfuntion of epithelial cells resulting in hair loss and digestive disorders, are frequent side eects of therapy with cytotoxic drugs (De Vita et al., 1993; MacDonald et al., 1995) . Besides the existence of multiple cytotoxic drugs, about 50% of the cancer patients still die after treatment (De Vita et al., 1993) . Thus, the availability of new cytotoxic drugs is a requirement for the successful treatment of cancer patients in the future.
Recent progress in the understanding of the mechanisms that regulate cell proliferation, differentiation and apoptosis is facilitating the development of new strategies based on the rational design of new antitumor agents (Kerr and Workman, 1994) . Thus, it is becoming more evident that tumor cells harbor alterations that subvert signal transduction cascades controlling these cellular processes. Speci®c interference with the aberrant signaling process pretends either reversion of the transformed phenotype or the selective destruction of tumor cells. Thus, the identi®cation of novel intracellular targets responsible for the alterations induced by the activity of dierent oncogenes and tumor suppressor genes, constitutes the basis for the rational design of novel antiproliferative and antitumor strategies (Kerr and Workman, 1994) . This strategy can also be applied to other diseases where alterations of the regulation of proliferation, dierentiation or apoptosis play a relevant role.
Previous studies have demonstrated that in cells transformed by oncogenes with high incidence in human tumors such as ras oncogenes (found in about 30% of all human tumors), there is a constitutive activation of choline kinase (ChoK) (Lacal et al., 1987; Macara, 1989; Lacal, 1990; Teegarden et al., 1990; Cuadrado et al., 1993; Carnero et al., 1994a; JimeÂ nez et al., 1995; Ratnam and Kent, 1995) , an enzyme that is responsible for the conversion of choline into phosphorylcholine (PCho) (Pelech and Vance, 1984) . The increase in ChoK activity results in elevated levels of PCho, a putative novel second messenger involved in proliferation (Cuadrado et al., 1993) . Furthermore, there is evidence that hemicholinium-3 (HC-3), the most potent drug known as a ChoK inhibitor, blocks DNA synthesis stimulation by growth factors such as PDGF, bFGF, EGF, or phorbol esters but not that of serum or insulin (Cuadrado et al., 1993) . Furthermore, HC-3 blockage is eective only when added up to 4 ± 6 h of addition of growth factors (JimeÂ nez et al., 1995) , suggesting that it is highly speci®c for a particular step in the cell cycle. All together, these results imply that PCho may be an essential element in some mitogenic routes and most likely those where Ras proteins are involved. Finally, recent NMR studies demonstrate that the levels of PCho are increased in a large number of tumor cells from mice and humans when compared to their normal counterparts (Bhakoo et al., 1996) . These results provide strong support to the hypothesis of an important role of phosphatidylcholine metabolites in the regulation of normal cell growth and that its alteration is important for the establishment of cancer cells.
Although the mechanism by which inhibition of PCho production blocks DNA synthesis is still unknown, it has been shown that it is not a consequence of interference with the interaction of growth factors with their receptors, nor an eect of inhibition of the receptor's tyrosine kinase activity (Cuadrado et al., 1993) . Neither does this eect result from interference with other known enzymes involved in phospholipid metabolism (Cuadrado et al., 1993) . However, it is possible that the observed antiproliferative eect of ChoK inhhibition by HC-3 is a consequence of non-speci®c interference with intracellular signaling cascades, since we have found that inhibition of PCho production by HC-3 interferes with the activation of the Raf/MAPK pathway induced by growth factors (JimeÂ nez et al., 1995) . Thus, the availability of more selective compounds capable of inhibiting ChoK would be essential to further establish the correlation of inhibition of PCho and blockade of the RAf/MAPK pathway.
The speci®c inhibition of processing and membrane localization of Ras proteins by blockage of the farnesylase, the enzyme that is responsible for this process, is proving to be a valid strategy for antitumor therapy where Ras proteins are involved (Kerr and Workman, 1994) . Although the Raf kinase constitutes one of the best known eectors for Ras proteins with which it associates after cell stimulation (Moodie et al., 1993; Zhang et al., 1993; Vojtek et al., 1993; Warne et al., 1993) , the precise mechanism for its full activation still remains unknown. Recently, it has been proposed that a lipid-derived molecule might be involved in this process (Dent and Sturgill, 1994) . Thus, blockade of PCho production may constitute a strategy for the speci®c inhibition of tumor cells where ras oncogenes are key players. On the other hand, the speci®city of the inhibitory eect observed in HC-3 treated cells (Cuadrado et al., 1993; JimeÂ nez et al., 1995) suggests that its eect is not due to non-speci®c toxicity and makes this compound an interesting model for the design of new antitumor agents. However, the antimitogenic action of HC-3 is achieved at high concentrations (Cuadrado et al., 1993; JimeÂ nez et al., 1995) and it is possible that it leads to its inhibitory eect on cells stimulated with growth factors as a consequence of some action on other pathways. Furthermore, HC-3 is a competitive inhibitor of the high anity choline transport system and has highly toxic respiratory paralyzant activity (Cannon, 1994) , making the use of HC-3 as an in vivo antiproliferative agent impossible. Thus, the ®rst step for the development of these potential anticancer chemicals aecting ChoK is to improve the potency of HC-3 without aecting its speci®city and antiproliferative activity. To this end, we have initiated a program for the synthesis of derivatives with increased inhibitory activity towards choline kinase. These new compounds have been useful to verify the involvement of ChoK in the regulation of cell proliferation. In this study we describe the synthesis of several derivatives based on structural modi®cations of HC-3 which improve the ChoK inhibitory activity of HC-3 up to 1000-fold ex vivo and 600-fold in vitro. Some of these novel compounds have antiproliferative activity which is more ecient towards oncogene-transformed cells where a constitutive increase in ChoK is observed. Thus, the results shown in this study establish that choline kinase is a potential novel target for the design of new antiproliferative drugs.
Results

Generation of new choline kinase inhibitors
Hemicholinium-3 (HC-3) is a competitive inhibitor of ChoK due to its structural homology to choline (Hamza et al., 1983) . The HC-3 structure, designated in this study as compound 1 (Figure 1 ), contains a central biphenyl ring to which two choline-like chains containing the quaternary groups are attached forming oxazinium rings in solution (Cannon, 1994) . The oxazinium rings are thought to host the HC-3 inhibitory activity (Cannon, 1994) . Although HC-3 is best known as a competitive inhibitor for choline uptake by blocking the high-anity sodium and chloride-dependent transport system (Guyenet et al., 1973; Polak et al., 1977; Zlatkine et al., 1993) , it can also aect choline acetyltransferase and choline kinase (Hamza et al., 1983; Cannon, 1994) . We have taken advantage of the inhibitory action of HC-3 against ChoK in this study to improve its action as ChoK inhibitor. The IC 50 for ChoK inhibition ex vivo was estimated as 500 mM using puri®ed ChoK from yeast.
Two series of compounds which are all symmetrical bis-quaternary derivatives were synthesized. The ®rst one consists of hemicholinium-like derivatives with the bis-phenacyl moiety linking several ammonium groups and pyridinium rings as the two terminal fragments (type 2 compounds. Table 1 ). In the second one, the modi®cations aect more drastically both the spacer and the two cationic heads of the prototype. These type 3 compounds have the general formula Het (Table 2) . Tables 1 and 2 show the structures, yields, melting points and analytical data for type 2 and 3 compounds, respectively.
Ex vivo action of HC-3 derivatives on ChoK
The analysis of the eect of the de®ned modi®cations of HC-3 structure was ®rst tested in an ex vivo system using puri®ed ChoK from yeast as a target. This assay allowed us to evaluate the eect on HC-3 activity without considering the possible eects on other properties such as permeability into intact cells, speci®c cellular environments, putative intracellular modi®cations of the synthesized compounds or enzyme compartmentalization. The results obtained with both types of compounds are summarized in Table 3 as their IC 50 for ChoK inhibition. It can be observed that some of the newly generated compounds show a dramatically increased activity compared to that of HC-3 under identical experimental conditions. Thus, while HC-3 had an IC 50 of 500 mM, FK21 had an IC 50 of 0.5 mM, a 1000-fold more active and other derivatives such as FK24 (143-fold), FK8 (71-fold), JCR89C (50-fold) were also shown to be much more potent. The other molecules improved HC-3 activity from 10-to 30-fold.
In vitro activity of novel ChoK inhibitors
Some of the above compounds were proved to be excellent ex vivo ChoK inhibitors with a great increase in the acitivity relative to HC-3, the best known inhibitor for this enzyme. In order to test whether they would be good inhibitors of ChoK in intact cells, we next investigated the inhibitory activity towards ChoK in whole NIH3T3 cells. For this, the levels of phosphorylcholine (PCho) were determined after incubation of the cells in the presence of increasing concentrations of each compound and [ 14 C]choline. Under the experimental conditions described in Materials and methods, HC-3 showed an IC 50 against ChoK of 600 mM for the in vitro activity. The results obtained using the most representative compounds from the ex vivo test are summarized in Table 3 as their IC 50 for ChoK inhibition. In contrast to the results observed in the ex vivo assay, some of the most active compounds were found to be relatively inactive for the in vitro inhibition of ChoK. This is the case for all type 2 compounds (FK21, FK8, FK24 and FK26) and some of the type 3 compounds (JCR951B and JCR927A). The reason for the lack of an eect is mostly due to the structure of these compounds that could make them highly unpermeant to intact cells. On the other hand, the other type 3 compounds showed a similar activity in the in vitro assay to that found under the ex vivo conditions, or even a slight increase in their inhibitory action. Their range of activity was from 1 ± 4.5 mM, which is 600-to 130-fold more potent than HC-3 under identical conditions. The dierences found between the ex vivo and the in vitro results may be a consequence of the dierent kinases used for the in vitro analysis (mouse ChoK), versus the ex vivo conditions (yeast ChoK). The speci®c environment of the choline kinase in the NIH3T3 cells may also play a role in the discrepancies. Finally, the experimental dierences for both assays could be important. In any case, these results indicate that a drastic improvement of up to 600-fold on the in vitro inhibition of ChoK was also obtained with several of the newly synthesized compounds.
Eect of ChoK inhibitors on DNA synthesis stimulated by growth factors
Once new compounds were identi®ed with a range of activities from 130 ± 600-fold increase on ChoK inhibition in intact cells, we aimed at the dilucidation of their putative activity as antimitogenic drugs as previously described for HC-3 (Cuadrado et al., 1993; JimeÂ nez et al., 1995) . We next analysed their inhibitory eect on DNA synthesis stimulation by either PDGF or serum. For this, JCR89C, JCR795B, JCR947A and JCR987B were chosen as some of the Inhibitory activity of the newly generated compounds on ChoK under ex vivo and in vitro conditions. The ex vivo data refers to the inhibitory activity of each compound towards the puri®ed ChoK from yeast. The in vitro data refers to the inhibitory activity of each compound using the NIH3T3 cells system. Numbers re¯ect concentrations of each compound, expressed as mM, to which 50% inhibition was obtained. Fold refers to the fold of increased activity in each case referred to the activity of HC-3 under identical conditions. ND: not determined best in vitro inhibitors of ChoK. As shown in Figure  2 , a drastic inhibition of DNA synthesis in response to PDGF was observed for all the compounds analysed that paralleled their eect on ChoK in vitro. Furthermore, similar results were also observed for bFGF ( Figure 2b ). All the compounds analysed were much more eective than HC-3 under identical conditions, with an IC 50 of 5 mM (Figure 2e ). Table 4 summarizes the results obtained as the IC 50 values for the compounds tested. The concentrations required for the inhibiton of DNA synthesis ranged from 100 ± 2500-fold lower than those required for a similar eect using HC-3. Thus, these novel compounds were much more eective both as inhibitors of ChoK in vitro and as inhibitors of DNA synthesis induced by growth factors than HC-3.
It has been previously demonstrated that the inhibitory eect of HC-3 on DNA synthesis in response to growth factors, is not a consequence of non speci®c toxicity, since no inhibition is observed in the presence of serum (Cuadrado et al., 1993; JimeÂ nez et al., 1995) and addition of HC-3 to cells 6 h after stimulation with growth factors also results in no inhibitory eect (JimeÂ nez et al., 1995) . Similar results were also observed when the most active ChoK inhibitors generated in this study were tested in the presence of serum (Figure 2 ). This eect was also consistent with their much higher in vitro inhibitory activity against ChoK, suggesting that inhibition of ChoK is most likely responsible for the blockage of DNA synthesis found in cells stimulated by growth factors.
Signal transduction pathways aected by speci®c ChoK inhibition
We have previously demonstrated that HC-3 is rather speci®c for ChoK since no inhibitory eect was observed against a series of phospholipases (Cuadrado et al., 1993) . Furthermore, HC-3 does not interfere with the interaction of growth factors with their receptors, nor the receptor's kinase activity determined by either autophosphorylation of the receptor or phosphorylation of endogenous substrates such as PI3K (JimeÂ nez et al., 1995) . However, an apparent speci®c interference with the activation of the Raf kinase/MAPK pathway was observed that paralleled inhibition of PCho Inhibitory activity of the newly generated compounds on DNA synthesis stimulated by PDGF in NIH3T3 cells. Numbers re¯ect concentrations of each compound, expressed as mM, to which 50% inhibition was obtained. Fold indicates the fold of increased activity in each case referred to the activity of HC-3 under identical conditions. ND: not determined production (JimeÂ nez et al., 1995) .Thus, we investigated the eect of the newly designed compounds on signaling pathways activated by growth factor's receptors. To that end, we investigated the eects of some of the best in vitro ChoK inhibitors with antiproliferative activity on endogenous signaling cascades related to regulation of proliferation. Thus, activation of PI3K, PI-PLC and PC-PLD, as well as the Raf/MAPK pathway were investigated.
No signi®cant eect was observed for any of the compounds used in the activation of PI3K induced by PDGF (Figure 3a) nor the activation of two of the most relevant enzymes involved in the regulation of phospholipid metabolism such as PI-PLC ( Figure 3b ) and PLD (Figure 3c ), consistent with our previous ®ndings using HC-3 as the mitogenic inhibitor. However, contrary to what is found with HC-3, none of the newly designed compounds analysed speci®cally interfered with activation of the Raf/ MAPK pathway in response to PDGF or serum at concentrations where a drastic inhibiton of ChoK was observed in intact cells. As shown in Figure 4 , activation of both p42MAPK and p44MAPK was observed after PDGF or serum addition even in the presence of JCR947A or JCR795B. Furthermore, contrary to what is observed with HC-3, the antiproliferative action of HC-3 derivatives can be dissected from the inhibitory eect on the Raf/MAPK pathway. Thus, these results provide further evidence that the speci®c inhibition of ChoK is indeed responsible for the antimitogenic action in response to growth factors.
Antiproliferative eects of HC-3 derivatives on oncogenes-transformed cells
Ras proteins regulate the activation of several intracellular signaling pathways upon mitogenic stimulation by growth factors. In addition to the well-known activation of the Raf/MAPK pathways, phospholipid metabolism is also regulated by Ras proteins (Lacal and Carnero, 1994) . At least four important enzymes involved in phospholipid metabolism are activated by ras oncogenes, two phospholipases: PLA 2 (Bar Sagi and Feramisco, 1986; Carnero et al., 1994a) and PLD (Carnero et al., 1994a,b; Carnero and Lacal, 1995) , and two kinases: PI3K (RodrõÂ guez Viciana et al., 1994) and ChoK (Lacal et al., 1987; Macara, 1989; Lacal, 1990; Teegarden et al., 1990; Cuadrado et al., 1993 Cuadrado et al., , 1994a JimeÂ nez et al., 1995; Ratnam and Kent, 1995) . 
Eect of ChoK inhibitors on signal transduction pathways: activation of MAPK. Cells were grown to con¯uence in plastic dishes, serum-starved for 24 h and treated with ChoK inhibitors for the indicated times prior to stimulation. Then, medium was replaced with 3 ml of DMEM containing either no stimulation (7), 20 ng/ml of PDGF-BB (PDGF) or 20% fetal bovine serum (FBS) and the indicated treatment. Stimulation proceeded at 378C for 10 min. HC-3 was used at 20 mM; JCR/ 947A and JCR/795B were used at 300 mM. These concentrations are at least threefold higher than the IC 50 for inhibition of thymidine incorporation for each compound. Western blot using an anti-MAPK antibody was performed by standard procedures. Migration sites for p42 and p44 and their phosphorylated, activated forms are indicated While the involvement of the Raf/MAPK pathway in the regulation of cell proliferation is well established, resulting in the regulation of several transcription factors (Moodie et al., 1993; Zhang et al., 1993; Vojtek et al., 1993; Warne et al., 1993) , the putative participation of the ras-activated lipid-related pathways is still not completely understood. A consequence of the activation of the PLD/ChoK pathway in ras-transformed cells, is a constitutive increase in the basal levels of PCho which seems critical for cell proliferation (Lacal et al., 1987; Cuadrado et al., 1993; JimeÂ nez et al., 1995) . Thus, we have investigated whether the speci®c inhibition of the ChoK-dependent generation of PCho is relevant for ras-transformation. To that end, we have incubated NIH3T3 cells transformed by the Harveyras oncogene with JCR/795B and compared their antiproliferative action to that observed versus untransformed NIH3T3 cells. A strong inhibition on proliferation was observed in the ras-transformed cells at concentrations as low as 10 mM of JCR/ 795B, which was not observed in the parental NIH3T3 cells (Figure 5a ). This antiproliferative eect was observed at all concentrations of serum tested, suggesting that although the mitogenic eect after 24 h treatment can be bypassed by serum, after prolonged treatments of up to 6 days, JCR/795B had an antiproliferative eect even in the presence of 10% serum. A higher dose of the ChoK inhibitor of 50 mM was also an ecient inhibitor of proliferation for both NIH3T3 and ras-transformed cells, a further indication that this compound may be cytotoxic. Moreover, the above results indicate a higher sensitivity of the ras-transformed cells to ChoK inhibition than their parental, untransformed cells, which correlates with their eects on PCho production. We also tested the other compounds with ecient in vitro inhibitory activity towards ChoK and antimitogenic activity on cells stimulated by growth factors under identical conditions to that of JCR/795B. Either JCR/89C, JCR/791B, JCR/947A and JCR987B showed similar responses and higher activity towards ras-transformed cells than the parental NIH3T3 cells ( Figure 5) .
As further controls, we also investigated the eect on cell proliferation of the new ChoK inhibitors in other oncogene-transformed cells with either increased or normal ChoK activity. We determined by two alternative methods that src-induced, but not fos-induced transformation is also associated with elevated levels of PCho, due to an increased ChoK activity, as previously demonstrated for ras. To that end we ®rst measured the kinetics of accumulation of radiolabelled PCho after a 2 ± 3 h incubation period with labelled choline. As shown in Figure 6a , both ras and src-transformed cells had an increased PCho production relative to their parental cell lines, an indication of a higher ChoK activity. By contrast, the fos-transformed cells had a ChoK activity not distinguishable from that of the control cells. We also determined the speci®c activity of ChoK in cell extracts from each of the transformed cell lines and found that both the ras-and src-transformed cells had an increased ChoK activity (Figure 6b ). By contrast, fos-transformed cells have normal levels of ChoK activity. We next investigated whether the src-and fos-transformed cells were more sensitive to the inhibitory eects of the ChoK inhibitors. As shown for ras, the src-transformed cells were more sensitive to the ChoK inhibitors than their parental NIH3T3 cells (Figure 7a ). By contrast, the fostransformed cells were similarly sensitive to the ChoK inhibitors as their parental counterparts (Figure 7b ). This eect was specially observed at the lower concentrations of each inhibitor tested (1 and 10 mM), with no signi®cant inhibition, analysed by the t-student test, in the case of the fos-transformed cells but a consistent, signi®cant reduction of the proliferation rates in the ras-and src-transformed cells. Figure 5 Eects on cell proliferation by ChoK inhibitors in rastransformed cells. (a) Eects of JCR/795B treatment: Cells were seeded on plastic plates and incubated for 24 h in DMEM supplemented with 10% NCS. Then, cells were incubated in DMEM containing the indicated amounts of serum and the indicated concentrations (10 or 50 mM) of JCR/795B. Three days later medium was aspirated from each well, fresh medium added containing identical concentrations of serum and JCR/795B, and cells maintained for three additional days. Quanti®cation of the cells remaining in each well was carried out basically using the crystal violet method (Gillies et al., 1986) . Data represent mean values of triplicate determinations reported as percentage of cells relative to their untreated controls, which is considered as 100% in each case. The experiment was repeated at least three times with similar results. (b) Untransformed NIH3T3 cells (&) and ras-transformed cells (hatched box) were grown under standard conditions and treated with the indicated concentrations (1, 10 or 50 mM) of each ChoK inhibitor in the presence of 2% serum, essentially as described in the legend to a. Data indicate the mean values of triplicate determinations. The experiment was repeated twice more with similar results. Variations were less than 15% among all samples. Values were statistically signi®cant by the tstudent test between P50.01 and P50.001
Finally, we have also expanded our studies to other oncogene-transformed cells such as raf and mos. To that end, we ®rst established the relative basal ChoK activities of both cell lines compared to their parental counterparts. As shown in Figure 8a , consistent with a previous report, transformation by raf induced an increase in basal ChoK activity (Ratnam and Kent, 1995) . Surprisingly, mos-transformed cells showed a much higher basal ChoK activity. As expected from the experiments shown before, both transformed cell lines were more sensitive in the antiproliferative assay when treated with one of the selected new compounds, JCR795B, than their parental counterparts (Figure 8b ). It is interesting to note that the mos-transformed cells, with higher basal ChoK levels, were more sensitive than those of raf-transformed cells, with lower relative basal ChoK levels. Altogether, these results provide a strong support to the hypothesis of an important role of ChoK in the signalling processes altered by oncogenes. Furthermore it also indicates that ChoK inhibition is in fact responsible for the speci®c antiproliferative eect of the new compounds.
Discussion
Previous studies from our group demonstrated that PCho levels increase in NIH3T3 cells after stimulation with growth factors and serum and are constitutively elevated in ras-transformed cells (Lacal et al., 1987; Cuadrado et al., 1993; Carnero et al., 1994a; JimeÂ nez et al., 1995) . The elevated level of PCho results from the consecutive action of phospholipase D and ChoK (Cuadrado et al., 1993; Carnero et al., 1994a; del Peso et al., 1997) . HC-3, the best ChoK inhibitor known until now, shows antimitogenic activity to NIH3T3 cells stimulated with speci®c growth factors such as PDGF, bFGF, EGF or phorbol esters but not serum (Cuadrado et al., 1993; JimeÂ nez et al., 1995) , an indication that this eect is not a consequence of nonspeci®c toxicity. Since these experiments were performed to establish DNA synthesis on a 24 h time period, they show the eect of these drugs on entry into the S phase. However they do not measure their eects on cell proliferation. Furthermore, HC-3 treatment is ecient only if added up to 6 h after mitogenic stimulation, an indication that it is aecting a rather speci®c step within the cell cycle previous to the commitment to enter the S phase (JimeÂ nez et al., 1995) . These results suggested that ChoK, and therefore generation of PCho, may be a critical event in mitogenic signal transduction induced by growth factors.
In this study we provide evidence that transformation by ras is more sensitive to ChoK inhibition than their parental cells. We also provide evidence that other oncogenes such as src and mos, and to a lesser extent raf, but not fos, induces increased basal ChoK activity. These results are in agreement with a recent report indicating that raf-transformed cells have also increased ChoK activity and elevated PCho levels (Ratnam and Kent, 1995) . They also suggest that several oncogenes may mediate transformation by altering signaling pathways which include those related to phospholipid metabolism. In keeping with these results, we have recently reported that oncogenes such as ras, src and met have similar eects on PLD regulation, while other oncogenes such as sis, fgr or fms do not (del Peso et al., 1997) . Furthermore, speci®c interference of these signaling pathways aecting phospholipid metabolism may be critical for dysregulated cell proliferation induced by speci®c oncogenes based on these dierential requirements. Our results demonstrate that this is the case for ras, src, mos and raf-transformed cells, which have increased PCho levels and increased sensitivity to ChoK inhibition. In contrast, fos-transformation does not aect PCho levels and therefore is as sensitive to ChoK inhibition for cell proliferation as their parental counterpart.
The concentrations of HC-3 required to inhibit ChoK are in the mM range. However, at these concentrations no inhibitory activity was found against several phospholipases tested under ex vivo conditions (Cuadrado et al., 1993) . No eect was observed either on ligand-receptor interaction for PDGF, nor inhibition of the autophosphorylation of the PDGF-receptor or the activation of its known endogenous substrates (JimeÂ nez et al., 1995) . By contrast, HC-3 blocked Raf kinase and MAPK activation induced by speci®c growth factors but not Figure 5 . Mean values of three experiments performed in triplicate each is shown using raf-and mos-transformed cells grown in 10% serum that induced by serum (JimeÂ nez et al., 1995) . These results led to two important suggestions: (1) the possible requirement of PCho for the activation of the Raf/MAPK pathway induced by growth factors, and (2) that the mechanism for growth inhibition of HC-3 is based on the inhibition of the Raf/MAPK pathway. However, due to the high concentrations of HC-3 required for these eects, de®nitive support to the hypothesis of ChoK involvement in the regulation of cell growth would depend upon the identi®cation of more active and more speci®c ChoK inhibitors that would reproduce these results.
Hemicholinium-3 (HC-3) is known as a potent inhibitor of choline uptake in cholinergic nerve terminals. Its activity is based on the competitive inhibition of the high anity, Na + -and Cl 7 -dependent choline transport system (Guyenet et al., 1973; Polak et al., 1977; Zlatkine et al., 1993) . HC-3 has a much less inhibitory eect on the low-anity sodium independent choline transport system, which is related to the biosynthetic pathway converting choline into phosphatidylcholine in all cell types (Tucek, 1985) . However, HC-3 also aects the biosynthesis of phosphorylcholine (PCho) by competitive inhibition of ChoK. In fact, HC-3 is actually also the most active inhibitor of ChoK known (Hamza et al., 1983; Cannon, 1994) . In this study, we have generated new compounds based on the structure of HC-3 with much more potent inhibitory activity towards ChoK. The new drugs have improved the inhibitory potency on ChoK up to 1000-fold under ex vivo conditions and up to 600-fold for in vitro activity in the NIH3T3 cells system.
We have also observed that the best newly generated inhibitors of ChoK under in vitro conditions act as antimitogenic agents in response to growth factors. Since the assay used was the induction of DNA synthesis after 24 h of stimulation, it provides evidence for the requirement of PCho for cell cycle progression into the S phase. Under these conditions, a great improvement versus the eect of HC-3 of up to 2500-fold was achieved. The mechanism for their action was found to be independent of an inhibitory eect on the activity of growth factor's receptors, since similar levels of PI-PLCg, PLD or PI3K activation were found in the absence or in the presence of saturating concentrations of each ChoK inhibitor. Furthermore, no inhibition of any of these enzymes was observed in the presence of the ChoK inhibitors, indicating that their mechanism of action is not mediated by interference with these signaling enzymes. In contrast to the results found for HC-3, no speci®c interference with the Raf/MAPK activation induced by PDGF was found. These results indicate that the anti-mitogenic eect of ChoK inhibition by the newly synthesized compounds can be separated from the inhibitory action on the Raf/MAPK pathway found for HC-3. Thus, the inhibition of cell proliferation by blockage of PCho production is not mediated by interference with the activation of the Raf/MAPK pathway, in agreement with a recent report where ChoK is placed downstream of Raf kinase (Ratnam and Kent, 1995) . Finally, the newly generated compounds were also bypassed when serum was used as the mitogenic agent, an indication that their inhibitory eect is not due to non-speci®c toxicity, but instead to interference with speci®c signaling pathways that may be supplemented by some serum components. Furthermore it reduces the ambiguity due to the high HC-3 concentrations used to inhibit DNA synthesis since the inhibitory eect is around 2500-fold more speci®c.
ras-transformed cells have increased constitutive levels of PCho due to an increased PLD and ChoK activity (Lacal et al., 1987; Macara, 1989; Lacal, 1990; Teegarden et al., 1990; Cuadrado et al., 1993; Carnero et al., 1994a,b; JimeÂ nez et al., 1995; Ratnam and Kent, 1995) . We provide further evidence in this study that src-, mos-and raf-, but not fos-induced transformation has a similar eect on activation of ChoK. These results demonstrate that several oncogenes, but not all, can induce an increase in the ChoK/PCho pathway, suggesting that this pathway may be relevant for regulation of cell proliferation. In keeping with this concept, NMR analysis of tumor samples from human beings has shown increased levels of PCho, when compared to their normal counterparts (Ronen et al., 1991 (Ronen et al., , 1992 . More recent studies also suggest that the levels of choline metabolites play important roles in both immortalisation and transformation, and in particular an increase in PCho levels is related to the transforming phenotype (Bhakoo et al., 1996) .
The fact that ras-transformed cells show increased ChoK acitivity and that this activation most likely re¯ects a direct relationship in the signal pathways activated by ras, provides strong support for a role of ChoK in speci®c mitogenic signal transduction pathways. We have also investigated the putative antiproliferative eect of the ChoK inhibitors in oncogenes-transformed cells. Contrary to the antimitogenic assay, performed for only 24 h in serum-deprived cells, the antiproliferative assay is performed in cells treated for six days and grown in the presence of serum. The results presented in this study indicate that ras-, src-, raf-and mos-but not fos-transformed cells are more sensitive to the antiproliferative eect of ChoK inhibitors than their parental counterparts, NIH3T3 ®broblasts. The fact that NIH3T3 cells are also sensitive to a higher dose of ChoK inhibtors indicate that interference with ChoK results in a cytotoxic or cytostatic eect. However, since fostransformed cells showed both levels of PCho and sensitivity to ChoK blockage similar to control cells, a non-speci®c side eect of the ChoK inhibition can be ruled out. Thus, an eective inhibition of oncogenesdependent signaling with ChoK as a target may be a useful strategy, as previously demonstrated for the inhibitors of the farnesylase responsible for Ras processing and membrane localization (Kerr and Workman, 1994) . The results shown in this study are of great relevance since they imply that generation of PCho by ChoK is an important step in the signaling pathways that govern cell growth by growth factors and oncogenes. It also provides evidence that ChoK may be used as a novel target for the design of intelligent drugs which may be used in the therapy against diseases such as cancer, where alteration of both ChoK activity and the levels of PCho have been reported. This would be particularly useful for tumor cells carrying ras and other activated oncogenes such as src, mos or raf.
Materials and methods
Synthesis
Compounds 2a, FK21 and 2c, FK24 were prepared by dissolving 1 mmol of a,a'-dibromo-4,4'-biacetophenone in a minimum amount of warmed tetrahydrofuran, adding 2 mmol of the corresponding tertiary amine with stirring and more solvent until the ®nal volume was 10 ml, and allowing the mixture to stir overnight at room temperature. Compound 2d, FK7 was prepared by warming 0.2 g of a,a'-dibromo-4,4'-biacetophenone in pyridine (5 ml) and stirring at room temperature for 3 h. The experimental procedure for type 3 compounds consisted simply of heating in a sealed tube at 1008C a solution of the heterocycle (1.10 mmol) and the corresponding bis(bromomethyl) compound BrCH 2 ACH 2 Br (0.54 mmol) in dry butanone (25 ml). In all cases, the solid which formed was recrystallized (see Table 1 and 2 for each particular case). After ®ltration, the product was left for 16 h at 408C in a vacuum oven at ca. 0.1 mmHg over phosphorus pentoxide. Melting points (mp) were obtained on an Electrothermal melting point apparatus and are non corrected. Many of the bis-salts were unavoidably analysed as solvates, owing to their tendency to retain water under the non-destructive drying conditions. Synthesis of compounds 2b, FK8 (Cannon et al., 1990) and 3a, JCR/89C (Campos Rosa et al., 1996) have been previously reported.
Bis-quaternization of the substituted pyridines and quinolines occurred smoothly, requiring less than 1 h when electron-donating substituents of the 4-dimethylamino and 4-amino type were present on the ring. The yields of the expected products were good. In contrast, when no substituents were present on the heteroaromatic ring, prolonged heating of the sealed tube was found to be necessary. A more detailed description of the synthesis procedures will be described elsewhere.
Cell cultures and reagents
Cells used in this study have been previously described (del Peso et al., 1997) . NIH3T3 mouse ®broblasts and their derivatives, the Harvy-ras-transformed cell line (H-ras) and the LP8.3 (ras), v-src and c-fos, were grown in Dulbecco's Modi®ed Eagle's medium (DMEM) supplemented with 10% new-born calf serum (Gibco, Grand Island, NY) Ex vivo assays of choline kinase activity Dierent concentrations of the new choline kinase inhibitors were incubated for 45 min at 378C with 10 mU/ml choline kinase from yeast in a buer containing 100 mM Tris pH 8, 100 mM MgCl 2 , 10 mM ATP and 200 mM methyl-[ 14 C]choline chloride (55 mCi/mmol, 2 mCi/ ml) in a ®nal volume of 50 ml. The reaction was stopped in ice by adding 10 ml 500 mM EDTA. Thirty ml of every sample were resolved in this layer chromatography plates (LK6D Silica gel 60 A, Whatman Inc. New Jersey) using as liquid phase 0.9% NaCl:methanol;ammonium hydroxide (50:70:5; V:V:V). Radioactive metabolites (Choline and Phosphocholine) were automatically quanti®ed by an electronic auto radiography system (Instantimager, Packard; Meriden, CT). The inhibitory concentrations at which 50% was reached (IC 50 ) were calculated using a semilogarithmic plotting of the ratio PCho/(PCho+Cho) versus concentration of the inhibitors.
Analysis of PCho production in cells (in vitro assay)
Cells (typically 1.5610 5 /well) were seeded on 6 well plates and incubated for 3 days. Then, cells were rinsed in TD buer (137 mM NaCl, 5 mM KCl, 20 mM Tris, pH 7.4), and 1 h before labeling with 0.5 mCi/ml methyl-[ 14 C]choline chloride, cells were incubated in DMEM supplemented with dierent concentrations of choline kinase inhibitors, and maintained for 14 additional hours. Then cells were rinsed in ice-cold TD and ®xed with 16% ice-cold trichloroacetic acid (TCA). TCA-soluble material containing choline and phosphorylcholine was washed three times with four volumes of diethyleter, dryed under vacuum and resuspended in water. Samples were resolved and quanti®ed as described for the ex vivo assay. IC 50 of phosphorylcholine production were then calculated using a semilogarithmic plotting of the PCho levels versus concentration of the inhibitors.
Analysis of choline kinase activity in dierent cell lines
Two dierent approaches were used to assess choline kinase activity in oncogene-transfected cells relative to their parental, non-trnaformed cell lines. One of the methods was to determine the levels of PCho per mg of protein after a short (2 ± 3 h) labeling period with 1 mCi/ml methyl-[
14 C]Cho. The experiment was carried out essentially as described above, except that the labeling period was shorter and no choline kinase inhibitors were added. The alternative method consisted in an ex vivo reaction using cell extracts from the dierent cell lines as a source of choline kinase. Brie¯y, monolayers of quiescent cells seeded on six well plates were lysed in a buer containing 0.5% Triton-X100, 0.5% sodium deoxycholate, 50 mM Tris, pH 7.5, 10 mM Na 4 P 2 O 7 , 50 mM NaF, 1 mM Na 3 VO 4 , 20 mg/ml leupeptin, 20 mg/ml aprotinin and 1 mM PMSF. After centrifugation at 13 000 r.p.m. for 30 min at 48C, 100 mg of protein were used as a source of choline kinase in the reaction described as`ex vivo choline kinase activity' in a ®nal volume of 100 ml. The reaction was stopped by adding ice-cold TCA to a ®nal concentration of 15%. After centrifugation at 13 000 r.p.m. for 30 min at 48C, 30 ml of the supernatants were resolved by thin layer chromatography on LK6D Silica gel 50 A plates as described above.
Mitogenic assays
Cells (typically 3610
4 /well) were seeded on 24-well plates and incubated for 3 days. Then cells were rinsed in TD and stimulated for 22 h with PDGF-BB (20 ng/ml), bFGF (20 ng/ml), or 20% serum in DMEM containing dierent concentrations of the inhibitors. Six hours before processing, 1 mCi/ml methyl-[ 3 H]thymidine was added and cells incubated under standard conditions of temperature, humidity and CO 2 atmosphere. [
3 H]thymidine incorporation into DNA replicating cells was determined as the amount of radioactivity present in TCA-insoluble material. The cells were rinsed once with TD and twice with ice-cold 16% TCA. Then, TCA-insoluble material was resuspended in 400 ml 0.25 N sodium hydroxide for 1 h. The solubilized solution was scintillation counted.
Western blot analysis of MAP-1K nd MAP-2K
Anti-MAP-1K and MAP-2K antibodies were generated as described in JimeÂ nez et al. (1995) . Cells were grown to con¯uence in dishes of 10 cm in diameter, and then serumstarved for 24 h and treated with ChoK inhibitors for the indicated times prior to stimulation. Then, medium was replaced with 3 ml of DMEM containing the indicated growth factors and treatments, and stimulation proceeded at 378C for 10 min. Incubations were terminated by aspirating o media, washing with TD buer and addition of 350 ml ice-cold lysis buer (150 mM NaCl, 0.5% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 7.5, 15 mM b-glycerophosphate, 10 mM Na 4 P 2 O 7 , 50 mM NaF, 0.1 mM Na 3 VO 4 , 20 mg/ml leupeptin, 1 mM PMSF). Nuclei and detergent-insoluble material were removed by centrifugation at 10 000 g for 10 min. The resulting supernatants were assayed for estimation of total cell protein (Bio-Rad, Rockville Centre, NY) and equal amounts of cell lysate (typically 45 mg) were boiled at 958C for 3 min in SDS ± PAGE sample buer. For Western blot analysis, proteins were electrophoresed onto 10% SDS ± PAGE gels (35% acrylamide, 0.6% bis-acrylamide) poured in 20620 cm glasses. Separated proteins were transferred to nitro-cellulose and the nitro-cellulose paper blocked for 2 h in 4% non-fat dried milk in T-TBS (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20). Blots were then incubated 2 h with a 1:1000 dilution of the polyclonal anti-MAPK antibody in the same solution. Blots were washed three times for 10 min in T-TBS, incubated 30 min with 1:1000 biotinylated anti-rabbit antibody (Amersham), washed three additional times for 10 min with T-TBS, and incubated for 30 min with 1:1000 streptavidin-horseradish peroxidase (Amersham) in T-TBS. After washing three times for 10 min with T-TBS, MAP-1 Kinase and MAP-2 Kinase were detected by the ECL protocol (Amersham). Activation of these enzymes in response to mitogens was assessed by the mobility shift produced as a consequence of their hyperphosphorylation.
Analysis of PI3K activity
Cells were grown to con¯uence in dishes of 10 cm in diameter, and then serum-starved for 12 ± 24 h and treated with the ChoK inhibitors at indicated times prior to stimulation. Then, medium was replaced with 2 ml of DMEM containing 20 ng/ml PDGF-BB and the indicated treatments. Stimulation proceeded for 10 min at 378C. Cells were then washed with cold TD buer, rinsed with buer A (137 mM NaCl, 20 mM Tris-HCl, pH 7.5, 1 mM MgCl 2 , 1 mM CaCl 2 , 1 mM Na 3 VO 4 ), and lysed in buer A containing 1% NP40 and 1 mM PMSF at 48C for 20 min. Insoluble material was removed by centrifugation at 10 000 g for 15 min. The supernatants were assayed for estimation of total cell protein and equal amounts of lysates were incubated with 10 ml of a mouse monoclonal anti-phosphotyrosine antibody (Amersham) overnight at 48C. Sepharose C14B protein A (Sigma) previously incubated with goat anti-mouse antibody (Cappel) was added and incubation proceeded for two additional hours. Immunoprecipitates were collected and washed three times with 1% NP40, 1 mM Na 3 VO 4 in TD buer, twice with 100 mM Tris-HCl, pH 7.5, 500 mM LiCl and twice with 100 mM Tris-HCl, pH 7.5, 100 mM NaCl, 5 mM EDTA. Immunoprecipitates were then assayed for phosphatidylinositol (PI) phosphorylation activity, as previously described (JimeÂ nez et al., 1995) .
Analysis of PLD activity
PLD activity was assayed measuring its transphosphatidylating properties (Carnero et al., 1994a) . Cells (typically 1.5610 5 /well) were seeded on 6-well plates and incubated for 3 days in the presence of 1 mCi/ml [ 14 C]glycerol. Cells were then treated without replacing the labeling medium with the indicated ChoK inhibitors. One hour later cells were washed with TD buer and incubated for 40 min with 0.5% 1-butanol in DMEM supplemented when indicated with 350 nM PDBu and ChoK inhibitors. Cells were then scrapped twice in 1 ml methanol, collected and mixed with 2 ml of chloroform and 1 ml water. The organic phase was dried in a 378C heating block under nitrogen stream and the lipids separated by TLC using as a liquid phase the upper part of a mixture of ethyl acetate:iso-octane:glacial acetic acid:water (90:50:20:100), (V:V:V:V) and 1.5 ml of acetic acid. Quanti®cation of the ratio phosphatidyl-butanol/cell lipids was carried out by Instantimager.
Analysis of PI-PLC activity
Cells (typically 1.5610 5 /well) were seeded on 6-well plates and incubated in inositol-free medium for 3 days in the presence of 2 mCi/ml myo-[ 3 H]inositol. Then cells were treated with ChoK inhibitors without replacing the labelling media. One hour later cells were incubated for 40 min with 25 mM LiCl in the presence or absence of inhibitors. Stimulation was carried out by adding 20 ng/ml PDGF-BB for 30 additional min. Incubation was stopped by washing with TD buer and inositol was dissolved in 1 ml 5% perchloric acid plus 1 ml water. Inositolphosphates (IPs) were separated using ion exchange chromatography (AG1-X8 Resin, Bio-Rad, Hercules, CA). Liquid phases were consecutively 5 mM Na 2 B 4 O 7 , 60 mM formic acid and 1.2 M (NH 4 )H 2 PO 4 , 100 mM formic acid. Lipids were obtained by adding 1 ml 0.25 N sodium hydroxide to each well. Radioactivity was scintillation counted and the ratio IPs/lipids was calculated.
Cell proliferation assays
Cells were seeded on 24-well plates and incubated for 24 h in DMEM supplemented with 10% NCS. Then, cells were washed with TD buer and incubated in DMEM containing the indicated amounts of serum and dierent concentrations of the ChoK inhibitors. Three days later wells were aspirated, fresh medium added, and cells maintained for three additional days. Quanti®cation of the cells remaining in each well was carried out using the crystal violet method (Gillies et al., 1986) , with some modi®cations. Brie¯y, cells were washed with TD buer and ®xed with 1% glutaraldehide for 15 min. After washing again with TD, cell nuclei were stained with 0.1% crystal violet for at least 30 min, and washed three times with distilled water. Adsorbed dye was resuspended in 10% acetic acid and absorbance at 595 nm was determined in a spectrophotometer. The statistical analysis of the eect of each ChoK inhibitor in oncogenetransformed versus their corresponding parental cell lines was performed by the t-student test.
